Cytosorbents Corp Files 8-K on Financials
Ticker: CTSO · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
TL;DR
Cytosorbents filed an 8-K detailing financial results and operations.
AI Summary
Cytosorbents Corporation filed an 8-K on January 3, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to its business as a surgical and medical instrument apparatus company. The company was formerly known as MedaSorb Technologies CORP and GILDER ENTERPRISES INC.
Why It Matters
This 8-K filing provides crucial updates on Cytosorbents Corporation's financial performance and operational status, which is important for investors and stakeholders to assess the company's health.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial results and does not indicate any unusual or significant risks.
Key Players & Entities
- Cytosorbents Corporation (company) — Registrant
- MedaSorb Technologies CORP (company) — Former company name
- GILDER ENTERPRISES INC (company) — Former company name
- January 3, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Cytosorbents Corporation's results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on January 3, 2025.
What industry does Cytosorbents Corporation operate in?
Cytosorbents Corporation operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry, SIC code 3841.
What were Cytosorbents Corporation's previous names?
Cytosorbents Corporation was formerly known as MedaSorb Technologies CORP and GILDER ENTERPRISES INC.
Where is Cytosorbents Corporation's principal executive office located?
Cytosorbents Corporation's principal executive office is located at 305 College Road East, Princeton, New Jersey 08540.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-01-03 16:20:17
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value CTSO The Nasdaq Stock Marke
Filing Documents
- tm251882d1_8k.htm (8-K) — 27KB
- tm251882d1_ex99-1.htm (EX-99.1) — 19KB
- tm251882d1_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-25-000811.txt ( ) — 239KB
- ctso-20250103.xsd (EX-101.SCH) — 3KB
- ctso-20250103_lab.xml (EX-101.LAB) — 33KB
- ctso-20250103_pre.xml (EX-101.PRE) — 22KB
- tm251882d1_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operation and Financial Condition On January 3, 2025, CytoSorbents Corporation issued a press release announcing certain preliminary and unaudited financial results and business updates for the quarter and year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated January 3, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) * The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 3, 2025 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer